-
NMPA accepts new drug listing application for rituximab
Time of Update: 2020-06-09
recently, Cinda Bio Pharmaceutical (http:// and Lilly Pharmaceuticals announced that the National Drug (http:// Regulatory Authority (NMPA) has accepted a joint development of the Drug (http
-
FDA approves new use of GlaxoSmithKline's asthma treatment Nucala (mepolizumab)
Time of Update: 2020-06-09
recently, GlaxoSmithKline (GSK) announced that the Us The FDA (http:// approved a new use of its asthma treatment, Nucala., As an IL-5 inhibitor, Nucala is a class of monoclonal antibody therap
-
New oral gel Ipshu ® for sale in China
Time of Update: 2020-06-09
Recently, Japan's Su Aikang Company (http:// and Li's Big Pharmaceutical S (Hong Kong) Co., Ltd., held in Chengdu, "Ipshu ® oral gel China listing meeting", officially announced the Ipshu ® marke
-
European Commission approves Pfizer Talazoparib for treatment of adultbreast cancer
Time of Update: 2020-06-09
recently, The European Commission (EC) has approved the targeted anti-cancer drug Talazoparib for the treatment of adult patients with 1/2 mutations in the type of breast cancer susceptibility gene
-
FDA approves Venetoclax for treatment of adult CLL/SLL
Time of Update: 2020-06-09
recently, the U.S Food drug (http:// Regulatory Authority ( FDA (http:// ) announced the approval of Venetoclax for the treatment of adult CLL/SLL The CLL14 study was a multicenter, open label
-
FDA formally accepts new NDA drug application for leppelzone reprieve microsphere Rykindo for green leaf pharmaceutical injection
Time of Update: 2020-06-09
Green leaf Pharmaceutical (http:// the group's independent lying innovative formulation, injection lipotone slow-release microsphere Rykindo (LY03004) is one step closer to being approved for lis
-
FDA approves nuclear output inhibitor XPOVIOTM (selinexor) in combination with low-dose dexamethasone for the treatment of RRMM
Time of Update: 2020-06-09
recently, deki Pharmaceutical (http:// and partner KaryopTherapeutics Inc (NASDAQ: KPTI) announced that the U.S Food and Drug (http:// Administration ( FDA (http:// ) has officially approved
-
FDA accepts new drug application for innovative Helicobacter pylori removal therapy Talicia
Time of Update: 2020-06-09
classified as a type 1 carcinogen for stomach cancer, Helicobacter pylori infection is one of the strongest risk factors for stomach cancer, and is also one of the main risk factors for peptic ulcer
-
Jansen announces positive results from new combination therapy (Darzalex-VTd therapy) in phase 3 trials of multiple myeloma
Time of Update: 2020-06-09
multiple myeloma is a malignant blood cancer caused by plasma cell cancer in the bone marrow , Janssen, a company owned by Johnson and Johnson, (http:// janssen ) has unveiled its heavy-duty singl
-
FDA approves Pfizer's avetin biosimilar drug bevadoford for treatment of five cancers
Time of Update: 2020-06-09
, Pfizer announced in the of the http:// (NYSE: PFE) that the u.S Food Drug (http:// Regulatory Authority http:// (http:// has approved the avastin ®, bevacizumab biosimilar drug bevanoviaan
-
Novo Nordisk and Jia ®'s listing application in China approved by NMPA
Time of Update: 2020-06-09
recently, the State Drug (http:// Regulatory Authority (NMPA) approved the launch of Novo nord nord Company's (http:// of the Novo and Jia® (Degumen Winter Double Insulin Injection) in China f
-
InD application for Arvinas candidate therapy ARV-471 obtains FDA approval
Time of Update: 2020-06-09
today, Pharmaceutical Sincon partner Arvinas (http:// announced that its application for inDD for its candidate therapy ARV-471 was approved by the FDA (http:// ARV-471 is an oral estrogen re
-
Pfizer announces innovation target drug Dozerun ® (Dacotinib) approved by China's National Drug Administration
Time of Update: 2020-06-09
recently, Pfizer (http:// announced that the innovative target of drug (http:// Dozerun ® (Dacostinib) on May 15 was approved by the State administration of Medicines and http:// Regulatory
-
Pfizer announces second-generation EGFR-tyrosine kinase inhibitor target drug Dacutinib (Dozerun ®) officially launched in China
Time of Update: 2020-06-09
lung cancer ranks first in the morbidity and mortality of all types of cancer in China Of these, NSCLC accounts for about 85% of all lung cancer cases In China, EGFR is the most common type of mutat
-
The State Drug Administration has conditional approval of the application for registration of the import of injections by Thedenosumab
Time of Update: 2020-06-09
recently, the State Drug Administration has conditionally approved the application for registration of the injection of Denosumab, which is not surgically removed or surgically removed for adults an
-
FDA approves Botox for pediatric patients suffering from upper limb spasms
Time of Update: 2020-06-09
recently, Allergan announced that the U.S Food and Drug (http:// Administration ( FDA (http:// ) has approved Botox (patox, generic name: onabotulinumtoxinA, Botox Toxin A) for the treatment of
-
Type A hemophilia gene therapy SB-525 achieved positive results in Phase 1/2 clinical trials
Time of Update: 2020-06-09
recently, Sangamo (http:// and Pfizer announced the latest results of their joint development of the type A hemophilia gene therapy SB-525 in the phase 1/2 clinical trial (http:// The results
-
CHMP recommends approval of Jansen Stelara (ustekinumab) extended indications
Time of Update: 2020-06-09
UC is a chronic disease of the colon caused by an abnormal response to the body's immune system, where inflammation of the inner wall of the colon occurs and ulcers are produced Symptoms of the dise
-
Qilu first imitation kidney cell carcinoma drug "Peeppelpani tablets" declared to be listed to obtain CDE acceptance
Time of Update: 2020-06-09
Renecell carcinoma is a common malignant tumor in the world, the morbidity and mortality rate accounts for about 2%-3% of systemic tumors, in the urinary system malignancies, the incidence of the in
-
Mercado's innovative antibiotic combination Recarbrio is approved by fda
Time of Update: 2020-06-09
today, the U.S FDA (http:// approved the listing of Recarbrio, an innovative antibiotic combination developed by the of Ms http:// to treat complex urinary tract infections (cUTI) and complex
